Regenxbio Company Profile (NASDAQ:RGNX)

About Regenxbio (NASDAQ:RGNX)

Regenxbio logoREGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RGNX
  • CUSIP: N/A
  • Web:
  • Market Cap: $573.27 million
  • Outstanding Shares: 30,821,000
Average Prices:
  • 50 Day Moving Avg: $19.34
  • 200 Day Moving Avg: $19.77
  • 52 Week Range: $7.07 - $24.55
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.69
  • P/E Growth: 0.29
Sales & Book Value:
  • Annual Revenue: $4.65 million
  • Price / Sales: 123.28
  • Book Value: $7.04 per share
  • Price / Book: 2.64
  • EBIDTA: ($75,960,000.00)
  • Net Margins: -661.81%
  • Return on Equity: -24.21%
  • Return on Assets: -23.16%
  • Current Ratio: 6.72%
  • Quick Ratio: 6.72%
  • Average Volume: 310,615 shs.
  • Beta: -0.58
  • Short Ratio: 6.59

Frequently Asked Questions for Regenxbio (NASDAQ:RGNX)

What is Regenxbio's stock symbol?

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

How were Regenxbio's earnings last quarter?

Regenxbio Inc (NASDAQ:RGNX) released its earnings results on Tuesday, May, 9th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.76) by $0.06. The company earned $0.46 million during the quarter. Regenxbio had a negative net margin of 661.81% and a negative return on equity of 24.21%. View Regenxbio's Earnings History.

Where is Regenxbio's stock going? Where will Regenxbio's stock price be in 2017?

2 equities research analysts have issued 1 year price targets for Regenxbio's stock. Their predictions range from $25.00 to $50.00. On average, they anticipate Regenxbio's stock price to reach $37.50 in the next twelve months. View Analyst Ratings for Regenxbio.

Who are some of Regenxbio's key competitors?

Who owns Regenxbio stock?

Regenxbio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (8.58%), Perceptive Advisors LLC (5.27%), Redmile Group LLC (4.79%), JPMorgan Chase & Co. (4.43%), Vanguard Group Inc. (3.70%) and Citadel Advisors LLC (2.11%). Company insiders that own Regenxbio stock include Donald J Hayden Jr, Fmr Llc, James E Flynn, Kenneth T Mills and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.

Who sold Regenxbio stock? Who is selling Regenxbio stock?

Regenxbio's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Morgan Stanley, Credit Suisse AG, FMR LLC, EAM Investors LLC, Bank of New York Mellon Corp, AXA and ProShare Advisors LLC. Company insiders that have sold Regenxbio stock in the last year include Donald J Hayden Jr, Kenneth T Mills and Vittal Vasista. View Insider Buying and Selling for Regenxbio.

Who bought Regenxbio stock? Who is buying Regenxbio stock?

Regenxbio's stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Citadel Advisors LLC, Vanguard Group Inc., JPMorgan Chase & Co., Perceptive Advisors LLC, Monashee Investment Management LLC, Weiss Multi Strategy Advisers LLC and Mirae Asset Global Investments Co. Ltd.. View Insider Buying and Selling for Regenxbio.

How do I buy Regenxbio stock?

Shares of Regenxbio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Regenxbio stock cost?

One share of Regenxbio stock can currently be purchased for approximately $18.60.

Analyst Ratings

Consensus Ratings for Regenxbio (NASDAQ:RGNX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.50 (101.61% upside)

Analysts' Ratings History for Regenxbio (NASDAQ:RGNX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/11/2017Chardan CapitalBoost Price TargetBuy -> Buy$35.00 -> $50.00HighView Rating Details
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$25.00N/AView Rating Details
4/8/2016Morgan StanleyBoost Price Target$34.00 -> $36.00N/AView Rating Details
10/12/2015Bank of America CorpInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Regenxbio (NASDAQ:RGNX)
Earnings by Quarter for Regenxbio (NASDAQ:RGNX)
Earnings History by Quarter for Regenxbio (NASDAQ:RGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.76)($0.82)$0.46 millionViewListenView Earnings Details
3/7/2017Y 2016($0.75)($0.74)$1.70 millionViewListenView Earnings Details
5/5/2016($0.40)($0.41)$0.39 millionViewN/AView Earnings Details
3/3/2016Q415($0.34)($0.20)$1.23 million$4.40 millionViewN/AView Earnings Details
11/5/2015Q315($0.35)($1.52)$1.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Regenxbio (NASDAQ:RGNX)
Current Year EPS Consensus Estimate: $-3.13 EPS
Next Year EPS Consensus Estimate: $-3.27 EPS


Dividend History for Regenxbio (NASDAQ:RGNX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Regenxbio (NASDAQ:RGNX)
Insider Ownership Percentage: 21.00%
Institutional Ownership Percentage: 64.31%
Insider Trades by Quarter for Regenxbio (NASDAQ:RGNX)
Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)
Insider Trades by Quarter for Regenxbio (NASDAQ:RGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/24/2017Donald J Hayden JrDirectorSell10,000$20.98$209,800.00View SEC Filing  
4/24/2017Kenneth T MillsInsiderSell15,440$20.98$323,931.20View SEC Filing  
4/24/2017Vittal VasistaCFOSell3,100$21.00$65,100.00View SEC Filing  
5/17/2016Fmr LlcInsiderSell18,300$12.41$227,103.00View SEC Filing  
5/16/2016Fmr LlcInsiderSell16,030$11.65$186,749.50View SEC Filing  
5/12/2016Fmr LlcInsiderSell6,711$10.85$72,814.35View SEC Filing  
5/11/2016Fmr LlcInsiderSell25,132$10.36$260,367.52View SEC Filing  
5/9/2016Fmr LlcInsiderSell10,570$9.94$105,065.80View SEC Filing  
5/4/2016Fmr LlcInsiderSell1,896$10.51$19,926.96View SEC Filing  
5/3/2016Fmr LlcInsiderSell6,046$10.76$65,054.96View SEC Filing  
4/29/2016Fmr LlcInsiderSell4,723$10.80$51,008.40View SEC Filing  
4/28/2016Fmr LlcInsiderSell33,196$11.23$372,791.08View SEC Filing  
4/26/2016Fmr LlcInsiderSell9,188$11.19$102,813.72View SEC Filing  
4/22/2016Fmr LlcInsiderSell20,558$11.30$232,305.40View SEC Filing  
4/20/2016Fmr LlcInsiderSell13,189$11.66$153,783.74View SEC Filing  
4/18/2016Fmr LlcInsiderSell18,900$11.75$222,075.00View SEC Filing  
4/14/2016Fmr LlcInsiderSell27,036$11.46$309,832.56View SEC Filing  
9/22/2015James E FlynnInsiderBuy175,000$22.00$3,850,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Regenxbio (NASDAQ:RGNX)
Latest Headlines for Regenxbio (NASDAQ:RGNX)
DateHeadline logo Regenxbio Inc (RGNX) Given Average Recommendation of "Strong Buy" by Analysts - May 12 at 10:41 PM logoREGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference - May 10 at 7:44 PM logoRegenxbio Inc (RGNX) Issues Quarterly Earnings Results - May 10 at 6:58 PM logoEdited Transcript of RGNX earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 11:13 AM logoInvestor Network: REGENXBIO, Inc. to Host Earnings Call - May 9 at 7:04 PM logoREGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights - May 9 at 7:04 PM logoRegenxbio reports 1Q loss - May 9 at 6:45 PM logoREGENXBIO, Inc. – Value Analysis (NASDAQ:RGNX) : May 5, 2017 - May 5 at 7:47 PM logoREGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : May 4, 2017 - May 4 at 7:45 PM logoPreclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be Presented at Upcoming Conferences - May 4 at 7:45 PM logoRegenxbio (RGNX) Getting Somewhat Positive Media Coverage, Report Shows - May 3 at 2:56 PM logo-$0.76 Earnings Per Share Expected for Regenxbio Inc (RGNX) This Quarter - May 2 at 8:02 PM logoREGENXBIO to Host Conference Call on May 9 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights - May 2 at 5:21 PM logoRegenxbio (RGNX) Earns Media Impact Rating of 0.25 - April 30 at 10:36 AM logoRegenxbio (RGNX) Getting Somewhat Negative Press Coverage, Study Shows - April 27 at 6:48 PM logoVittal Vasista Sells 3,100 Shares of Regenxbio Inc (RGNX) Stock - April 26 at 11:38 PM logoInsider Selling: Regenxbio Inc (RGNX) Director Sells 10,000 Shares of Stock - April 26 at 11:32 PM logoRegenxbio Inc (RGNX) Insider Kenneth T. Mills Sells 15,440 Shares - April 26 at 11:30 PM logoREGENXBIO Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares - April 26 at 5:46 PM logoRegenxbio (RGNX) Receiving Very Positive Media Coverage, Report Finds - April 18 at 9:24 AM logoChardan Capital Increases Regenxbio Inc (RGNX) Price Target to $50.00 - April 17 at 7:56 AM logoRegenxbio (RGNX) Given Daily News Impact Score of -0.04 - April 15 at 2:13 PM logoRegenxbio Inc (RGNX) Upgraded to Hold at Zacks Investment Research - April 15 at 7:12 AM logoRegenxbio Inc (RGNX) Expected to Post Quarterly Sales of $0.00 - April 13 at 12:14 PM logoRegenxbio Inc (RGNX) Lowered to "D+" at TheStreet - April 11 at 2:45 PM logoZacks: Analysts Expect Regenxbio Inc (RGNX) Will Post Earnings of -$0.76 Per Share - April 11 at 2:13 PM logoRegenxbio Inc. (RGNX) PT Raised to $50 at Chardan Capital Markets on News Dr. Olivier Danos is New CSO; 'Watershed Moment' - April 11 at 10:02 AM logoREGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : April 5, 2017 - April 7 at 12:14 PM logo Regenxbio Inc (RGNX) Given $30.25 Consensus Target Price by Analysts - April 6 at 8:04 AM logoRegenxbio Inc (RGNX) Raised to "Hold" at Zacks Investment Research - March 29 at 8:29 AM logoREGENXBIO Enhances and Expands Scientific Leadership - March 28 at 7:20 PM logoREGENXBIO Prices Public Offering Of 3.70 Mln Shares At $20.50/Shr - March 27 at 3:23 PM logoRegenxbio Inc (RGNX) Stock Rating Upgraded by Zacks Investment Research - March 23 at 7:00 PM logoRegenxbio Leads Biotech Movers Ahead of Market's Open - March 22 at 7:27 PM logoRegenxbio (RGNX) Reports Pricing of 3.7M Share Offering at $20.50 - March 22 at 8:42 AM logoREGENXBIO Announces Pricing of Public Offering of Common Stock - March 22 at 12:18 AM logoRegenxbio (RGNX) Plans $75M Common Stock Offering - March 21 at 7:17 PM logoRegenxbio Inc. (RGNX) Is Heading Lower After Offering Announcement - March 21 at 7:17 PM logoZacks Investment Research Lowers Regenxbio Inc (RGNX) to Sell - March 11 at 10:54 AM logoREGENXBIO INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 8 at 7:45 PM logo6 Stocks Trending Up With Big Volume - March 8 at 8:43 AM logoREGENXBIO's (RGNX) CEO Ken Mills on Q4 2016 Results - Earnings Call Transcript - March 8 at 12:25 AM logoREGENXBIO Announces Initiation of Phase I/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia - March 7 at 7:25 PM logoQ4 2016 Regenxbio Inc Earnings Release - Before Market Open - March 7 at 9:27 AM logoRegenxbio Inc Earnings Call scheduled for 4:30 pm ET today - March 7 at 9:27 AM logoREGENXBIO to Host Conference Call on March 7 to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights - February 28 at 5:46 PM logoREGENXBIO Honors Rare Disease Day® 2017 - February 28 at 5:46 PM logoRockville gene therapy company to begin trials for treatment for leading cause of blindness - February 16 at 7:11 PM logoREGENXBIO Announces IND Active for Phase I Trial of RGX-314 to Treat Wet Age-Related Macular Degeneration - February 15 at 12:49 AM logoREGENXBIO to Present at the 6th Annual LEERINK Partners Global Healthcare Conference - February 9 at 11:11 PM



Regenxbio (RGNX) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff